Volume 79, Issue 6, Pages (March 2011)

Slides:



Advertisements
Similar presentations
Volume 68, Issue 4, Pages (October 2005)
Advertisements

Volume 82, Issue 9, Pages (November 2012)
Volume 74, Issue 12, Pages (December 2008)
Volume 66, Issue 5, Pages (November 2004)
Agnes B. Fogo, MD, Mark A. Lusco, MD, Behzad Najafian, MD, Charles E
Renal manifestations in Fabry disease and therapeutic options
Paraneoplastic glomerulopathies: New insights into an old entity
Podocyte involvement in human immune crescentic glomerulonephritis
A. Evan, J. Lingeman, F.L. Coe, E. Worcester  Kidney International 
Volume 76, Issue 12, Pages (December 2009)
Quiz Page American Journal of Kidney Diseases
J.M. Henderson, S. al-Waheeb, A. Weins, S.V. Dandapani, M.R. Pollak 
AJKD Atlas of Renal Pathology: Chronic Antibody-Mediated Rejection
Modeling the Glomerular Filtration Barrier: Are You Kidney-ing Me?
AJKD Atlas of Renal Pathology: Fibrillary Glomerulonephritis
Volume 74, Issue 12, Pages (December 2008)
Volume 80, Issue 10, Pages (November 2011)
Glomerular disease related to anti-VEGF therapy
AJKD Atlas of Renal Pathology: Fabry Nephropathy
Patricia L. St. John, Dale R. Abrahamson  Kidney International 
Non-amyloid fibrils in heavy chain deposition disease
Volume 71, Issue 10, Pages (May 2007)
Proteinuria: an enzymatic disease of the podocyte?
Volume 78, Issue 2, Pages (July 2010)
Lecithin-Cholesterol Acyltransferase (LCAT) Deficiency
Proteinuria in diabetic kidney disease: A mechanistic viewpoint
Glomerular filtration: the charge debate charges ahead
Marie Claire Gubler, Corinne Antignac  Kidney International 
Volume 68, Issue 4, Pages (October 2005)
The online measurement of hemodialysis dose (Kt): Clinical outcome as a function of body surface area  Edmund G. Lowrie, Zhensheng Li, Norma Ofsthun,
Volume 70, Issue 8, Pages (October 2006)
Erik H. Strøm, Michael J. Mihatsch  Kidney International 
Estimation of podocyte number: A comparison of methods
Comorbidity and confounding in end-stage renal disease
Volume 57, Issue 1, Pages (January 2000)
Volume 73, Issue 7, Pages (April 2008)
Dominique A. Joly, Jean-Pierre Grünfeld  Kidney International 
Volume 54, Issue 2, Pages (August 1998)
Volume 82, Issue 9, Pages (November 2012)
Volume 66, Issue 1, Pages (July 2004)
Timothy A. Sutton, Pierre C. Dagher  Kidney International 
U-shaped effect of eGFR and mortality
Volume 66, Issue 5, Pages (November 2004)
Volume 67, Issue 4, Pages (April 2005)
Prevention of mesangial sclerosis by bone marrow transplantation
Therapy of relapsing minimal-change disease in adults: a new approach?
Obesity-related glomerulopathy: An emerging epidemic
Volume 81, Issue 5, Pages (March 2012)
AJKD Atlas of Renal Pathology: Idiopathic Nodular Sclerosis
Volume 85, Issue 3, Pages (March 2014)
AJKD Atlas of Renal Pathology: Minimal Change Disease
AJKD Atlas of Renal Pathology: Diabetic Nephropathy
Methods for guideline development
Volume 68, Issue 4, Pages (October 2005)
Michael W. Steffes, Derek Schmidt, Rebecca Mccrery, John M. Basgen 
Tatsumi Moriya, Thomas J. Groppoli, Youngki Kim, Michael Mauer 
New drug toxicities in the onco-nephrology world
Volume 57, Issue 5, Pages (May 2000)
Red cell traverse through thin glomerular basement membrane
R. Tapia, F. Guan, I. Gershin, J. Teichman, G. Villegas, A. Tufro 
Accelerated expression of senescence associated cell cycle inhibitor p16INK4A in kidneys with glomerular disease  B. Sis, A. Tasanarong, F. Khoshjou,
Volume 80, Issue 10, Pages (November 2011)
Volume 90, Issue 3, (September 2016)
Membranous and crescentic glomerulonephritis in a patient with anti-nuclear and anti- neutrophil cytoplasmic antibodies  A. Chang, O. Aneziokoro, S.M.
Volume 75, Issue 6, Pages (March 2009)
Volume 80, Issue 9, Pages (November 2011)
Wilhelm Kriz, Karlhans Endlich, Dr  Kidney International 
Volume 56, Issue 6, Pages (December 1999)
Role of altered renal lipid metabolism and the sterol regulatory element binding proteins in the pathogenesis of age-related renal disease  T.A.O. Jiang,
Tissue proteomics: a new investigative tool for renal biopsy analysis
Presentation transcript:

Volume 79, Issue 6, Pages 663-670 (March 2011) Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease  Behzad Najafian, Einar Svarstad, Leif Bostad, Marie-Claire Gubler, Camilla Tøndel, Chester Whitley, Michael Mauer  Kidney International  Volume 79, Issue 6, Pages 663-670 (March 2011) DOI: 10.1038/ki.2010.484 Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 1 Globotriaosylceramide (GL-3) inclusions in glomerular podocytes (arrowhead), endothelial cells (double arrowhead), and mesangial cells (spiral arrow) from the kidney biopsy of a Fabry patient (TEM×11,000). C, capillary lumen; E, endothelial cell; GBM, glomerular basement membrane; M, mesangium; PC, podocyte; TEM, transmission electron microscopy. Kidney International 2011 79, 663-670DOI: (10.1038/ki.2010.484) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 2 Relationship between age and podocyte (Vv(Inc/PC)), mesangial (Vv(Inc/Mes)), and endothelial cell (Vv(Inc/Endo)) globotriaosylceramide (GL-3) fractional volume of inclusions per cytoplasm and foot process width (FPW) in Fabry patients. (• represents male and ○ female; the bold line is the regression line and the dashed lines are 95% confidence interval boundaries). Kidney International 2011 79, 663-670DOI: (10.1038/ki.2010.484) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 3 Relationships between urinary protein/creatinine ratio (UPCR, mg/g) and foot process width (FPW, nm), globotriaosylceramide (GL-3) inclusion fractional volume per podocyte cytoplasm (Vv(Inc/PC)), and mesangial cell cytoplasm (Vv(Inc/Mes)) in Fabry patients. (• represents male and ○ female; the bold line is the regression line and the dashed lines are 95% confidence interval boundaries). Kidney International 2011 79, 663-670DOI: (10.1038/ki.2010.484) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 4 The grid used to estimate percent endothelial fenestration composed of an unbiased counting frame with inclusion (dashed) and exclusion (continuous) borders, and parallel lines 4mm apart. There is one coarse line (where the intercepts with endothelial coverage are counted) per seven fine lines. The short lines on the coarse lines are 4mm apart and, similar to fine lines, are used to define fenestrated vs non-fenestrated coverage. The endothelial coverage was arbitrarily called non-fenestrated if the distance between the two fenestrae on either side of the coarse line was more than 3 fine and coarse lines, and otherwise it was called fenestrated. Kidney International 2011 79, 663-670DOI: (10.1038/ki.2010.484) Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 5 Comparison of capillary endothelial coverage (arrows) in kidney biopsies from a normal subject (left) and a Fabry patient (right). Note that fenestration is markedly reduced in the Fabry biopsy. C, capillary; E, endothelial cell; PC, podocyte. Kidney International 2011 79, 663-670DOI: (10.1038/ki.2010.484) Copyright © 2011 International Society of Nephrology Terms and Conditions